Advances in the delivery of treatments for Parkinson's disease (Q36316936)

13 August 2017

1 reference

title

Advances in the delivery of treatments for Parkinson's disease (English)

1 reference

13 August 2017

1 reference

2

Susan H Fox

1 reference

13 August 2017

3

Jonathan M Brotchie

1 reference

13 August 2017

1

Tom H Johnston

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 November 2005

1 reference

Expert Opinion on Drug Delivery

13 August 2017

published in

1 reference

13 August 2017

volume

2

1 reference

13 August 2017

issue

6

1 reference

13 August 2017

page(s)

1059-1073

1 reference

Parkinson's disease. First of two parts

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Parkinson's disease. Second of two parts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Levodopa-induced dyskinesia in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Continuous dopamine-receptor stimulation in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Dopamine receptor agonists in the therapy of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Pergolide-induced pleuropulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Entacapone does not induce conformational changes in liver mitochondria or skeletal muscle in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Deprenyl in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of tradi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Etiological and therapeutical observations in a case of belly dancer's dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Duodenal levodopa infusion in Parkinson's disease--long-term experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

A controlled trial of rotigotine monotherapy in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Long-term observation of chronic subcutaneous administration of lisuride in the treatment of motor fluctuations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Biochemical and behavioral recovery in a rodent model of Parkinson's disease following stereotactic implantation of dopamine-containing liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Evaluation of rat striatal L-dopa and DA concentration after intraperitoneal administration of L-dopa prodrugs in liposomal formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

A pulmonary formulation of L-dopa enhances its effectiveness in a rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Transplantation of embryonic dopamine neurons for severe Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Delivery of GDNF by an E1,E3/E4 deleted adenoviral vector and driven by a GFAP promoter prevents dopaminergic neuron degeneration in a rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Enhanced gene expression in mouse muscle by sustained release of plasmid DNA using PPE-EA as a carrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Neuronal expression of the transcription factor Gli1 using the Talpha1 alpha-tubulin promoter is neuroprotective in an experimental model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Subthalamic GAD gene therapy in a Parkinson's disease rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Potential of transdermal drug delivery in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

Skin penetration and mechanisms of action in the delivery of the D2-agonist rotigotine from surfactant-based elastic vesicle formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2.6.1059

10.1517/17425247.2.6.1059

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference